Podcasts about indivior

This week we are joined by Jason Foster, CEO of Ori Biotech to talk about the future of CGT and why scalable strategic manufacturing is in a make or break moment, his experience scaling Indivior from 5 to 1,100 people culminating in a £3B exit and the powerful culture behind that growth, the Bluebird Bio acquisition and what it means for CGT investment today, and why he is deeply optimistic about Ori Biotech's automated, closed platform. A must-listen for anyone building, investing in, or scaling the next era of biotech.

In this update on the Suboxone Tooth Decay Lawsuit, Stan Gipe describes a “big step” – a step that may not seem big to plaintiffs, but is significant to the team that's driving a mass tort against Suboxone's manufacturer.That step is a census so that the team – operating as a firm called Dolman Russo – vets each person it represents. The census asks claimants for information such as proof that they used Suboxone's sublingual film, now linked to tooth decay. The team will also start asking claimants to sign release forms so the defense can secure their medical information.A member of the Dolman Russo steering committee, Stan explains to colleague and host Matt Dolman: “I think we've been more aggressive and more proactive about getting records for our clients than just about any other firm out there. It's going to force everyone to be proactive. It's going to force everyone to go out there and get those records.”The team is also reviewing electronically stored information for evidence of what the manufacturer, Indivior, knew or should have known about Suboxone's dangers.Want to learn more about the Suboxone Tooth Decay Lawsuit? Reach out to Dolman Law Group or Dolman Russo.Learn More and Connect☑️ Matt Dolman | LinkedIn☑️ Stan Gipe☑️ Dolman Law Group☑️ Dolman Law Group on LinkedIn, Facebook, Instagram, YouTube☑️ Subscribe: Apple Podcasts | Spotify | YouTubeThe insights and views presented in this podcast are for general information purposes only and should not be taken as legal advice for any individual case or situation. The information presented is not a substitute for consulting with an attorney. Nor does tuning in to this podcast constitute an attorney-client relationship of any kind. Any case result information provided on any portion of this podcast should not be understood as a promise of any particular result in a future case. Dolman Law Group Accident Injury Lawyers: Big firm results, small firm personal attention.

In this episode of the Recovery Matters Podcast, host Phil welcomes Ahmed Abdel Aziz from Indivior, a global pharmaceutical company focused on addiction medicine. Ahmed introduces himself and discusses his passion for public health and addiction treatment. He highlights Indivior's commitment to transforming lives affected by substance use disorders, emphasizing the need to treat addiction as a disease, not a moral failing. Ahmed shares insights into common misconceptions about medication-assisted recovery and explains the importance of patient-centric and culturally competent care. They explore the evolving landscape of addiction recovery, including the potential of psychedelics and the principles of harm reduction. Ahmed also reflects on his personal journey and motivations for working in this field, rooted in early exposure to the pharmaceutical industry and personal experiences with friends affected by addiction. The conversation delves into broader societal perspectives on healthcare and the evolving role of big pharma in addressing public health challenges. 00:00 Introduction and Guest Welcome 00:19 Ahmed Abdel Aziz's Background and Indivior's Mission 01:33 Common Medications and Misconceptions 03:51 Ahmed's Personal Journey into Addiction Medicine 06:46 Family and Future Generations 08:46 Shifts in Addiction and Recovery Perspectives 12:37 Multiple Pathways to Recovery 22:10 Hot Topics: Psychedelics and Harm Reduction 29:27 Big Pharma and Population Health 36:41 Spirituality and Recovery Coaching 43:54 Conclusion and Final Thoughts

The lawsuit against the manufacturer of Suboxone, a medication prescribed to help opioid addicts get clean but which causes tooth decay, continues on several fronts. In this update, David v. Goliath hosts Matt Dolman and Stan Gipe outline two recent developments for clients and potential clients. First, they are now bringing cases in states that had a one- or two-year statute of limitations on product liability claims. Second, they are mining electronically stored information to discover materials that may reveal why the manufacturer, Indivior, put this product on the market when a potential safer alternative was available. Tune in to learn the latest.Learn More and Connect☑️ Matt Dolman | LinkedIn☑️ Stan Gipe☑️ Dolman Law Group☑️ Dolman Law Group on LinkedIn, Facebook, Instagram, YouTube☑️ Subscribe: Apple Podcasts | Spotify | YouTubeThe insights and views presented in this podcast are for general information purposes only and should not be taken as legal advice for any individual case or situation. The information presented is not a substitute for consulting with an attorney. Nor does tuning in to this podcast constitute an attorney-client relationship of any kind. Any case result information provided on any portion of this podcast should not be understood as a promise of any particular result in a future case. Dolman Law Group Accident Injury Lawyers: Big firm results, small firm personal attention.

Attorneys general from 16 states, including Virginia, have reached an -million settlement with Indivior, the manufacturer of buprenorphine-based products used to treat opioid dependence. Participating states will split the settlement over a five-year period. The attorneys general claimed that Indivior violated federal law by marketing its products to physicians who were known to prescribe high volumes of opioids, and that the company failed to monitor suspicious orders for products, which led to them being inappropriately prescribed. The settlement was led by the attorneys general of New York, Illinois, Tennessee, Utah, and Virginia, with help from an executive committee of attorneys...Article LinkSupport the Show.

Send us a Text Message.Cary Claiborne is CEO of Adial Pharmaceuticals ( https://www.adial.com/ ), a clinical-stage biopharma company focused on developing therapies for the treatment of addiction and related diseases, specifically Alcohol Use Disorder (AUD). In the U.S. alone, an estimated 35 million people suffer from AUD, resulting in significant health, social and financial costs. Current treatment options present significant barriers to patient adoption, including abstinence and side effects, which can lead to social stigmatization.Mr. Claiborne has over three decades of experience in leadership roles with clinical and commercial stage, publicly traded biopharmaceutical companies. Most recently, Mr. Claiborne served as Chief Financial Officer and director of Indivior PLC, a publicly traded specialty pharmaceutical company developing medicines to treat addiction and serious mental illnesses. He led Indivior's spin-off from its then parent company, Reckitt Benckiser, to become an independent, publicly traded company. Prior to joining Indivior, Mr. Claiborne served as the CFO of Sucampo Pharmaceuticals, Inc., a global biopharmaceutical company, which was later sold to Mallinckrodt. Before joining Sucampo, Mr. Claiborne served as CFO and Corporate Secretary of Osiris Therapeutics, Inc. during the company's initial public offering.Mr. Claiborne currently sits on the boards of NeuroSense Therapeutics, a clinical-stage drug development company that is advancing a treatment for people living with amyotrophic lateral sclerosis, and CytRx Corporation, a biopharmaceutical company focused on discovering and developing new cancer therapeutics. Mr. Claiborne graduated from Rutgers University with a B.A. in Business Administration and earned his M.B.A from Villanova University and was a National Association of Corporate Directors (NACD) Governance Fellow.Support the Show.

In this CME episode, Dr. Andrew Cutler interviews Desiree Matthews, PMHNP-BC on the importance of engaging patients across all facets of tardive dyskinesia management beginning with screening to symptoms monitoring to treatment. The role of patient experience and preferences in shared decision-making regarding treatment for tardive dyskinesia is discussed at length.  Target Audience: This activity has been developed for the healthcare team or individual prescriber specializing in mental health. All other healthcare team members interested in psychopharmacology are welcome for advanced study. Learning Objectives: After completing this educational activity, you should be better able to: Recognize the significance of comprehensive measures that assess both healthcare practitioner-perceived severity of tardive dyskinesia symptoms and the patient-reported impact of tardive dyskinesia on daily life Engage in informed discussions with patients about the rationale behind incorporating additional medications to manage side effects arising from primary antipsychotic medication Consider all facets of patient health, including physical, mental, and social well-being, when formulating strategies for managing tardive dyskinesia symptoms Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Activity Overview: This activity is available with audio and is best supported via a computer or device with current versions of the following browsers: Mozilla Firefox, Google Chrome, or Safari. A PDF reader is required for print publications. A post-test score of 70% or higher is required to receive CME/CE credit. Estimated Time to Complete: 1 hour. Released: June 05, 2024*   Expiration: June 04, 2027 *NEI maintains a record of participation for six (6) years. CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD24-01-TD Credit Designations: The following are being offered for this activity: Physician: ACCME AMA PRA Category 1 Credits™ NEI designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity Nurse: ANCC contact hours NEI designates this Enduring Material for a maximum of 1.00 ANCC contact hours Nurse Practitioner: ACCME AMA PRA Category 1 Credit™ American Academy of Nurse Practitioners National Certification Program accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME. The content in this activity pertaining to pharmacology is worth 0.5 continuing education hour(s) of pharmacotherapeutics. Pharmacy: ACPE application-based contact hours This internet enduring, knowledge-based activity has been approved for a maximum of 1.00 contact hour(s) (.10 CEUs). The official record of credit will be in the CPE Monitor system. Following ACPE Policy, NEI must transmit your claim to CPE Monitor within 60 days from the date you complete this CPE activity and is unable to report your claimed credit after this 60-day period. Physician Associate/Assistant: AAPA Category 1 CME credits NEI has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit(s) for activities planned in accordance with the AAPA CME Criteria. This internet enduring activity is designated for 1.00 AAPA Category 1 credit(s). Approval is valid until June 04, 2027. PAs should only claim credit commensurate with the extent of their participation. Psychology: APA CE credits Continuing Education (CE) credits for psychologists are provided through the co-sponsorship of the American Psychological Association (APA) Office of Continuing Education in Psychology (CEP). The APA CEP Office maintains responsibility for the content of the programs. Social Work: ASWB-ACE CE credits As a Jointly Accredited Organization, NEI is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this internet enduring course receive 1 general continuing education credits. Non-Physician Member of the Healthcare Team: Certificate of Participation NEI awards hours of participation (consistent with the designated number of AMA PRA Category 1 Credit(s)™) to a participant who successfully completes this educational activity. Peer Review: The content was peer-reviewed by an MD specializing in psychiatry — to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Any relevant financial relationships were mitigated prior to the activity being planned, developed, or presented. Faculty Author / Presenter Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry and Behavioral Sciences, Norton College of Medicine, State University of New York Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Malvern, PA Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Brii Biosciences, Cerevel, Corium, Delpor, Evolution Research, Idorsia, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Lundbeck, LivaNova, Luye, MapLight Therapeutics, Neumora, Neurocrine, NeuroSigma, Noven, Otsuka, Relmada, Reviva, Sage Therapeutics, Sumitomo (Sunovion), Supernus, Takeda, Teva, Tris Pharma, VistaGen Therapeutics Speakers Bureau: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, BioXcel, Corium, Idorsia, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sumitomot (Sunovion), Supernus, Takeda, Teva, Tris Pharma, Vanda Data Safety Monitoring Board (DSMB): COMPASS Pathways, Freedom Biosciences Faculty Author / Presenter Desiree M. Matthews, MSN, PMHNP-BC Founder and Clinical Director, Different MHP, PC, Charlotte, NC Consultant/Advisor: Alkermes, Biogen, Boehringer Ingelheim, Karuna, Indivior, Janssen Pharmaceuticals, Neurocrine Biosciences, Sage Therapeutics, Takeda, Teva Speakers Bureau: AbbVie, Axsome, Neurocrine Biosciences, Teva The remaining Planning Committee members, Content Editors, Peer Reviewer, and NEI planners/staff have no financial relationships to disclose. NEI planners and staff include Caroline O'Brien, Meghan Grady, and Andrea Zimmerman. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competency and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me. Accessibility Statement Contact Us: For questions regarding this educational activity, or to cancel your account, please email customerservice@neiglobal.com. Support: This activity is supported by an unrestricted educational grant from Neurocrine Biosciences.

In this LegalCast episode hosted by Mark York, attorneys Sara Papantonio of Levin Papantonio and Davis Cooper of Cooper Law Partners discuss the Suboxone MDL 3092 (Multi-District Litigation). Sara and Davis, both recently appointed to the plaintiff's steering committee, provide insights into the litigation's background, key claims, and notable corporate misconduct. They highlight the significant dental injuries caused by Suboxone film, attributing them to the acidic nature of the drug. The discussion covers various legal aspects, including failure to warn claims, design defects, and antitrust violations by companies like Indivior and Reckitt Benkiser. The attorneys emphasize the importance of filing meritorious cases and the urgency for potential plaintiffs to seek representation due to statute of limitations constraints. They express confidence in the viability of the plaintiff pool and the strength of their case against the defendants. The episode concludes with a call for collaboration and potential co-authoring of articles to raise awareness in mainstream media about the ongoing litigation.   https://www.levinlaw.com/ http://www.cooperlawpartners.com

Justice Speaks continues JSI's series of interviews with Justice leaders by interviewing Dr. William Morrone, Medical Director of Recovery Pathways and the Shiawassee 35th Circuit Drug Court, Assistant Professor of Nursing at Johns Hopkins University, Faculty of Family and Community Medicine, at Michigan State University College of Osteopathic Medicine (MSUCOM).  The discussion covers substance use disorder and medications that can aid in recovery. This episode is sponsored by Indivior.

Jennifer Johnson talks about the recently published GSK results, which showed strong growth, but the ongoing Zantac litigation is hanging over the shares. The team also touch on the prospects of rival pharma companies AstraZeneca and Indivior.Our US-based journalist Arthur Sants joins from New York to unpack the growth, capex and future returns worries investors may have about the Magnificent Seven.It's then on to food producers AG Barr and Premier Foods with Mark Robinson, who shares news of trading updates, a new CEO sourced from an unlikely sector, and the prospects for growth.Last on the agenda, Mark shares the thinking behind his latest feature on regulation and how investors can get involved with the companies using it to their advantage.Dan Jones is joined by Jennifer Johnson, Alex Newman, Arthur Sants and Mark Robinson.Timestamps1:34 GSK and pharmaceutical firms15:20 US Tech stocks 28:58 AG Barr and Premier Foods36:22 RegulationMentioned in this episodeSemiconductor industry split between AI and the restGSK's RSV vaccine success makes its shares look cheapIrn Bru maker AG Barr buoyed by new subsidiariesThree companies benefitting from more regulationFTSE 350 Review: The drinks brands likely to grow in a struggling marketFTSE 350 Review: Will GSK replace Astra as the investor favourite?FTSE 350 Review: Software companies scramble to find AI uses Hosted on Acast. See acast.com/privacy for more information.

In this CME episode, Dr. Andrew Cutler interviews Dr. Stephen Stahl and Dr. Sarah Vinson about the ethicality and morality of involuntary treatment for serious mental illness (SMI), the relationship between SMI and the criminal justice system, and community-based changes that are being pursued to improve treatment and reduce the criminalization of SMI. Optional CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD23-SMI Learning Objectives: After completing this educational activity, you should be better able to: Recognize the neuroethics involved in involuntary treatment of serious mental illness Identify methods to prevent patients with serious mental illness from entering the criminal justice system, including the utility of diversion programs Institute community-based changes that have the potential to reduce the criminalization of serious mental illness, both on the individual and the policy level Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change. A posttest score of 70% or higher is required to receive CME/CE credit. The content in this activity does not pertain to pharmacology and is worth 0.0 continuing education hour of pharmacotherapeutics. Credit Types: The following are being offered for this activity: Nurse Practitioner: ANCC contact hours Pharmacy: ACPE application-based contact hours Physician: ACCME AMA PRA Category 1 Credits ™ Physician Associate: AAPA Category 1 CME credits Psychology: APA CE credits Social Work: ASWB-ACE CE credits Non-Physician Member of the Healthcare Team: Certificate of Participation stating the program is designated for AMA PRA Category 1 Credits™ Interprofessional Continuing Education: IPCE credit for learning and change Peer Review: The content was peer-reviewed by an MD specializing in forensic psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from commercial bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose any relevant financial relationships. Potential conflicts of interest are identified and mitigated prior to the activity being planned, developed, or presented. Interviewer Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA Consultant/Advisor: AbbVie, Acadia, Alfasigma, Alkermes, Axsome, Biogen, BioXcel, Boehringer Ingelheim, Cerevel, Corium, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Neumora, Neurocrine, Noven, Otsuka, Relmada, Sage Therapeutics, Sunovion, Supernus, Teva, Tris Pharma, VistaGen Therapeutics Speakers Bureau: AbbVie, Acadia, Alkermes, Axsome, BioXcel, Corium, Intra-Cellular, Ironshore, Janssen, Jazz, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris Pharma Interviewees Stephen M. Stahl, MD, PhD, DSc (Hon.) Clinical Professor, Department of Psychiatry and Neuroscience, University of California, Riverside School of Medicine, Riverside, CA Adjunct Professor, Department of Psychiatry, University of California, San Diego School of Medicine, La Jolla, CA Honorary Visiting Senior Fellow, University of Cambridge, Cambridge, UK Editor-in-Chief, CNS Spectrums Director of Psychopharmacology Services, California Department of State Hospitals Grant/Research: Acadia, Alkermes, Allergan/AbbVie, Arbor, AssureX, AstraZeneca, Avanir, Axovant, Biogen, Boehringer Ingelheim Braeburn, BristolMyer Squibb, Celgene, CeNeRex, Cephalon, Daiichi Sankyo-Brazil, Dey, Eisai, Forest, Genomind, Glaxo Smith Kline, Harmony Biosciences, Indivior, Intra-Cellular, Ironshore, Janssen, JayMac, Jazz, Lilly, Lundbeck, Merck, Neurocrine, Neuronetics, Novartis, Otsuka, Pear, Pfizer, Reviva, Roche, Sage, Servier, Shire, Sprout, Sunovion, Supernus, Takeda, Teva, Tonix, Torrent, Vanda Consultant/Advisor: Acadia, Adamas, Alkermes, Allergan/AbbVie, Altus, Arbor, AstraZeneca, Avanir, Axovant, Axsome, Biogen, Biomarin, Biopharma, Celgene, Cerevel, ClearView, Clexio, Concert, DepotMed, Done, EMD Serono, Eisai, Enveric, Eurolink, Fabre-Kramer, Ferring, Forest, Gedeon Richter, Genetica, Genomind, Innovative Science Solutions, Impel, Intra-Cellular, Ironshore, Janssen, Jazz, Karuna, Libbs, Lilly, Lipidio, Longboard, Lundbeck, Merck, Neos, NeuraWell, Neurocrine, NeuroPharma, Novartis, Noveida, Otsuka, Perrigo, Pfizer, Pierre Fabre, Proxymm, Recordati, Relmada, Reviva, Sage, Saniona, Servier, Shire, Sprout, Sunovion, Supernus, Takeda, Taliaz, Teva, Tonix, Tris, Trius, Vanda, Vertex, Viforpharma Speakers Bureau: Acadia, Allergan/AbbVie, Genentech, Janssen, Lundbeck, Merck, Neurocrine, Otsuka, Servier, Sunovion, Takeda, Teva Options Holdings: Delix, Genomind, Lipidio, NeuraWell Sarah Y. Vinson, MD, FAPA Interim Department Chair; Clinical Associate Professor; Director, Child and Adolescent Psychiatry Fellowship Program; Department of Psychiatry and Behavioral Sciences, Morehouse School of Medicine, Atlanta, GA Medical Director, Substance Abuse and Mental Health Services Administration (SAMHSA) African American Behavioral Health Center of Excellence, Atlanta, GA No financial relationships to disclose. Pre-Interview Author Sabrina K. Bradbury-Segal, PhD Senior Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose. The Planning Committee, Content Editor, and Peer Reviewer have no financial relationships to disclose. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competencies and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and strategies for understanding and reducing implicit bias can be found in this handout—download me. Support: This activity is supported by an unrestricted educational grant from Alkermes. Released: July 25, 2023      CME/CE credit expires: July 24, 2026

Ian King speaks to AJ Bell about how more British companies are listing on the US stock market. Plus, hear from the pharmaceutical company Indivior's chief executive about efforts to tackle an opioid crisis. And find out more about the Black Founders Fund - a scheme aimed at tackling the lack of black talent in tech start-ups.

A $145M opioid acquisition, biobucks for the holidays, a series A, and diabetes approvalsFind out more athttps://LifeScienceTodayPodcast.comStory ReferencesIndivior + OpiantRegeneron + CytomXRezoProventionAbout the ShowLife Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It's news, with a dash of perspective, focused on the life science industry. 

Adding to the information on opioid use disorder (OUD) provided during Episode 65 of the NP Pulse: The Voice of the Nurse Practitioner® podcast, AANP Fellow Dr. Laura Leahy and AANP member Colleen Barry return to share their expertise and knowledge on various aspects of OUD management and patient education. Resources from this episode: OUD Point of Care Tool  This activity is supported by educational funding provided by Indivior, Inc. Learn more about AANP at aanp.org and explore dozens of continuing education activities for NPs in the AANP CE Center.

Marketing operations is different in every industry. That's no less true for healthcare, a space notorious for stringent conditions on compliance. Of course, that adds a very important layer to consider when developing a robust strategy. Good thing there are people like Mark Clark, Senior Manager Marketing Operations at Indivior, who get the value of cross-collaboration and breaking down barriers within a company. Mark has been in the sales field, marketing, and marketing operations his whole career. But he's also worked in compliance-heavy industries that whole time, making him uniquely qualified to bring all parties to the table to mitigate risk in profound ways. Join us as we discuss: Developing a “big picture” mindset for the whole company The intersection of risk management, revenue, and operations Managing the evolving field of marketing operations

Nurse practitioners (NPs) Dr. Laura Leahy, an AANP Fellow, and Colleen Barry, an AANP member, join the NP Pulse: The Voice of the Nurse Practitioner® podcast to share their expertise on opioid use disorder (OUD). In this episode, they discuss their experience and offer insights on various aspects of OUD, inspiring NPs to consider the importance of using non-stigmatizing words to create a safe place for patients to be open with their health care professionals.   This activity is supported by educational funding provided by Indivior, Inc.

Today Andy Silvester takes us through the headlines: there's news about Indivior; the Financial Stability Board has issued a warning about crypto; and Heineken is raising prices to limit increasing costs. Andy also chats to City A.M.'s Sascha O'Sullivan and Jack Barnett about the latest ONS inflation numbers, the cost of living, and Boris Johnson. See omnystudio.com/listener for privacy information.

Welcome to another episode of Think Compliance. In this episode, we are join us as we are discussing a big DOJ announcement: Indivior Solutions Pleads Guilty To Felony Charge And Indivior Entities Agree To Pay $600 Million To Resolve Criminal And Civil Investigations As Part Of DOJ’s Largest Opioid Resolution   Join in our discussion with Ahmed Salim, a Compliance Professional, and Dagmar Austin of Compliatric.   For our new listeners, Compliatric created this podcast series to assist healthcare and compliance professionals in building their programs. In each Podcast, we discuss a new compliance topic and provide insight on how to ensure your organization is following best practices.

Schizophrenia is a chronic and debilitating disorder that creates a substantial burden not only for patients but also for their families. The high rates of treatment resistance, relapse rates, and incidence of adverse side effects in patients with schizophrenia suggest that a major treatment gap continues to exist. Given the high rates of treatment resistance, novel strategies and therapeutic approaches beyond D2 receptor blockade are being intensively studied. What are some of these novel approaches? How effective are they in the treatment of schizophrenia? What medications are available, or emerging that target neurotransmitters systems beyond dopamine? In this podcast episode, Dr. Jonathan Meyer and Dr. Leslie Citrome discuss some of the ground-breaking work in this field, and how you can better treat patients with schizophrenia. Optional CME Credits / Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME credit, click HERE. Learning Objectives: After completing this educational activity, you should be better able to: Describe clinical advances in our understanding of schizophrenia Describe novel treatments for schizophrenia Accreditation and Credit Designation Statements: The Neuroscience Education Institute (NEI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. NEI designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. A posttest score of 70% or higher is required to receive CME credit.  Nurses and Physician Assistants: for your CE requirements, the ANCC and NCCPA will accept AMA PRA Category 1 Credits™ from organizations accredited by the ACCME. The content in this activity pertains to pharmacology and is worth 0.75 continuing education hour of pharmacotherapeutics. Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME activity. Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships. Although potential conflicts of interest are identified and resolved prior to the activity being presented, it remains for the participant to determine whether outside interests reflect a possible bias in either the exposition or the conclusions presented. Interviewer / Author Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Grant/Research: Acadia, Aevi Genomics/Cerecor, Alder/Lundbeck, Akili Interactive, Alkermes, Allergan, Axsome, Biohaven, Daiichi Sankyo, Intra-Cellular, Ironshore, Janssen, Lilly, Lundbeck, Neurocrine, Novartis, Otsuka, Sage, Sunovion, Supernus, Takeda, Tris Consultant/Advisor: Acadia, Adlon, AiCure, Akili Interactive, Alfasigma, Alkermes, Allergan, Avanir, Cognitive Research, Intra-Cellular, Ironshore, Janssen, Lundbeck, MedAvante-ProPhase, Neurocrine, Novartis, Noven, Otsuka, Purdue, Sage, Sunovion, Supernus, Takeda, Teva Speakers Bureau: Acadia, Alfasigma, Alkermes, Allergan, Arbor, Avanir, Gedeon Richter, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris Interviewee / Author Leslie Citrome, MD, MPH Clinical Professor, Department of Psychiatry and Behavioral Sciences, New York Medical College, Valhalla, NY Consultant/Advisor: Acadia, Alkermes, Allergan, Avanir, BioXcel, Eisai, Impel, Indivior, Intra-Cellular Therapies, Janssen, Lundbeck, Luye, Merck, Neurocrine, Noven, Osmotica, Otsuka, Pfizer, Sage, Shire, Sunovion, Takeda, Teva, Vanda Speakers Bureau: Acadia, Alkermes, Allergan, Janssen, Lundbeck, Merck, Neurocrine, Otsuka, Pfizer, Sage, Shire, Sunovion, Takeda, Teva Stockholder: Bristol-Myers Squibb, Lilly, Johnson & Johnson, Merck, Pfizer Interviewee / Author Jonathan M. Meyer, MD Clinical Professor, Department of Psychiatry, University of California, San Diego School of Medicine, La Jolla, CA Consultant/Advisor: Acadia, Alkermes, Allergan, Intra-Cellular Therapies, Neurocrine Speakers Bureau: Acadia, Alkermes, Allergan, Janssen, Neurocrine, Otsuka, Sunovion, Teva Pre-Interview Author Sabrina K. Bradbury-Segal, PhD Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose. The Planning Committee and Peer Reviewer have no financial relationships to disclose. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural and Linguistic Competency: A variety of resources addressing cultural and linguistic competency can be found in this linked handout. Support: This activity is supported by an unrestricted educational grant from Intra-Cellular Therapies. Released: July 23, 2020          CME credit expires: July 23, 2023

In this Twin Petes Investing podcast number 26, the topics, stocks and shares discussed include: Winning stocks ytd Gold MelloVirtual Live Twin Petes Investing podcast Covid19 Testing outsourcing Land Securities / LAND Retail shopping Property Hedging Ocado / OCDO Scottish Mortgage Investment Trust / SMT Polar Capital Technology Trust / PCT Worldwide Healthcare Trust / WWH Petropavlovsk / POG Psychology AO World / AO. BATM Advanced Communications / BVC CMC Markets / CMCX IG Group / IGG Indivior / INDV Avacta / AVCT Powerhouse Energy Group / PHE Resolute Mining / RSG Dixons Carphone / DC. Appreciate Group / APP Best of the Best / BOTB Long-term investing Mistakes Patience Artificial Intelligence / AI Confirmation Bias Bullish indicators Bear indicators Online retail FTSE 100 FTSE 250 FTSE Allshare AIM Running your winners Buying bargains Risks Investing Trading & much more PLEASE SUBSCRIBE FOR FREE TO THIS PODCAST

En este nuevo episodio de Value Investing FM, Adrián y Paco tenemos el placer de entrevistar a Luis García y Michael Morosi, gestores del fondo Behavioral Fund de Mapfre Asset Management. Nos hablarán de: - Sus inicios en el mundo de la inversión en bolsa y las finanzas - Su estilo de inversión, que incluye análisis macro, catalizadores y economía del comportamiento - Algunas de las posiciones del Behavioral Fund: Olimpique de Lyon, Ajax de Amsterdam, TechnoGym o Unieuro. - Algunos de los errores de inversión que han cometido, como Indivior o SNC Lavalin. - Sus consejos para empezar a invertir para principiantes - Sus recomendaciones de libros para iniciarse en la inversión

En este nuevo episodio de Value Investing FM, Adrián y Paco tenemos el placer de entrevistar a Luis García y Michael Morosi, gestores del fondo Behavioral Fund de Mapfre Asset Management. Nos hablarán de: - Sus inicios en el mundo de la inversión en bolsa y las finanzas - Su estilo de inversión, que incluye análisis macro, catalizadores y economía del comportamiento - Algunas de las posiciones del Behavioral Fund: Olimpique de Lyon, Ajax de Amsterdam, TechnoGym o Unieuro. - Algunos de los errores de inversión que han cometido, como Indivior o SNC Lavalin. - Sus consejos para empezar a invertir para principiantes - Sus recomendaciones de libros para iniciarse en la inversión

Episode 12 - April 2019 Topic: Tackling Opioid Use Disorder in the Hospital Setting Guest: Richard Bottner, PA-C Support for this episode of Vital Minds is provided by Indivior, a global specialty pharmaceutical company with a 20-year legacy of patient advocacy and health policy, as well as education on evidence-based treatment models. Resources: Ascension Seton/The University of Texas at Austin Dell Medical School - Inpatient Buprenorphine Induction for Opioid Use Disorder Ascension Seton/The University of Texas at Austin Dell Medical School - Inpatient Management of Opioid Use Disorder: Buprenorphine/Naloxone Ascension Seton/The University of Texas at Austin Dell Medical School - Buprenorphine/Naloxone (Suboxone) Nursing Quick Reference Sheet Ascension Seton/The University of Texas at Austin Dell Medical School - Buprenorphine/Naloxone (Suboxone) Pharmacist Quick Reference Sheet SAMHSA TIP 63 Part 2: Addressing Opioid Use Disorder in General Medical Settings Massachusetts Health & Hospital Association - Guidelines for Medication for Addiction Treatment for Opioid Use Disorder within the Emergency DepartmentRead more ›

On this week's Companies & Markets Show editor John Hughman is joined by Harriet Russell, who's signing off after five and a half eventful years covering pharma and retail with a week of big stories from both sectors – including good news for GSK and Tesco, and predictably bad news for Indivior and Debenhams. See acast.com/privacy for privacy and opt-out information.

Episode 10 - January 2019 Topic: Addressing Addiction in PA Practice Guest: Gianni Migliaccio, PA-C Support for this episode of Vital Minds is provided by Indivior, a global specialty pharmaceutical company with a 20-year legacy of patient advocacy and health policy, as well as education on evidence-based treatment models. Resources: National Institute on Drug Abuse Addiction Medicine in Primary Care Substance Abuse and Mental Health Services Administration Integrating Addiction and Primary Care Services Qualify for NP and PA Waivers Society of PAs in Addiction Medicine The Commonwealth Fund - "In Focus: Expanding Access to Addiction Treatment Through Primary Care" Harvard Medical School CME Online - "Understanding Addiction" NCBI - "Estimating Demand for Primary Care-Based Treatment for Substance and Alcohol Use Disorders" Read more ›

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

Today in FirstWord:

Today in FirstWord: